CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE

心力衰竭的慢性 β 受体阻滞剂治疗

• 批准号: 7376447
• 负责人: E MICHAEL GILBERT
• 金额: $ 6.34万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376447
• 关键词: antihypertensive agents; beta antiadrenergic agent; blood pressure; heart failure; hemodynamics; reduction

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic beta-blocker treatment in heart failure is associated with increases in systolic function, improvement in hemodynamics, reversal of pathologic remodeling , improvement of symptoms, a reduction in hospitalization and a reduction in mortality. Chronic beta-blocker treatment in heart failure is associated with increases in systolic function, improvement in hemodynamics, reversal of pathologic remodeling, improvement of symptoms, a reduction in hospitalization and a reduction in mortality. The clinical evidence for the long-term benefit of beta-blocker therapy is so strong that it is now recommended therapy in all patients with class II or III heart failure symptoms who do not have specific contraindications. This study will investigate whether tolerance to the alpha 1-adrenoceptor blocking effects of carvedilol develops with chronic carvedilol therapy. We will measure the blood pressure and heart rate response to phenylephrine (a pure alpha 1-agonist) infusions in 17 subjects with heart failure. These measurements will be made prior to the initiation of carvedilol therapy, during the uptitration of carvedilol, and after 6 months of continuous carvedilol therapy. The dose of phenylephrine required to increase systolic blood pressure by 20 mm Hg (PS20) and the dose of phenylephrine required to increase diastolic blood pressure by 20 mm Hg (PD20) will be measured. Dose ratios at these doses will be calculated and compared. Prior to enrollment, a blood sample will be obtained to analyze alpha 1-adrenoceptor polymorphisms that could affect the individual's response to phenylephrine.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。慢性-受体阻滞剂治疗心力衰竭与收缩功能增强、血流动力学改善、病理性重塑逆转、症状改善、住院率降低和死亡率降低相关。慢性-受体阻滞剂治疗心力衰竭与收缩功能增强、血流动力学改善、病理性重塑逆转、症状改善、住院率降低和死亡率降低相关。临床证据表明-受体阻滞剂治疗的长期益处是如此之强，以至于它现在被推荐用于所有没有特定禁忌症的II或III级心力衰竭患者。本研究将探讨慢性卡维地洛治疗是否会产生对- 1肾上腺素受体阻断作用的耐受性。我们将测量17例心力衰竭患者对苯肾上腺素（一种纯α 1激动剂）输注的血压和心率反应。这些测量将在卡维地洛开始治疗前、卡维地洛增加剂量期间和卡维地洛连续治疗6个月后进行。测量使收缩压升高20mm Hg （PS20）所需的苯肾上腺素剂量和使舒张压升高20mm Hg （PD20）所需的苯肾上腺素剂量。将计算和比较这些剂量的剂量比。在登记之前，将获得血液样本来分析可能影响个体对苯肾上腺素反应的α 1-肾上腺素受体多态性。